A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
for
NASH With Fibrosis, MASH With Fibrosis
Location: Birmingham AL, Dothan AL, Chandler AZ, Mesa AZ,
Sponsor: Akero Therapeutics, Inc
Sex: All
Age: 18 - 70+
Code: NCT06215716
Phase3, Recruiting
Active & Responsive
Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment